MUC5AC and chronic obstructive pulmonary disease: Next, we investigated the effect of pannexin channel inhibitor, CBX or the P2R antagonist, suramin on the poly(I:C)-potentiated expression of MUC5AC in differentiated HBECs from COPD patients.